Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tenofovir disoproxil fumarate + emtricitabine + ethinyl estradiol + levonorgestrel
- Development stage
- Unknown
- Lead developer
- Viatris
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The 2PR (two-pill regimen) is a combination therapy used as the control arm in clinical trials conducted by the HIV Prevention Trials Network (HPTN), such as PC952 and PC953. It consists of two separate daily oral tablets: Truvada (a fixed-dose combination of tenofovir disoproxil fumarate and emtricitabine) for HIV pre-exposure prophylaxis (PrEP) and a combined oral contraceptive containing ethinyl estradiol and levonorgestrel. The regimen is intended for women at risk of both HIV infection and unintended pregnancy. Tenofovir and emtricitabine function as nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) to prevent HIV replication, while ethinyl estradiol and levonorgestrel act as hormonal contraceptives to prevent ovulation and pregnancy. The trials evaluate whether a single-pill Dual Prevention Pill (DPP) improves adherence compared to this standard two-pill approach.
- Brand names
- Truvada
- Other names
- Two-pill regimenTDF/FTC + EE/LNG2PR-HIV Prevention Trials Network-HIV infection-pregnancy
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseER (Estrogen receptor)PR (Progesterone receptor)
Beyond the preview
Go deeper on tenofovir disoproxil fumarate + emtricitabine + ethinyl estradiol + levonorgestrel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tenofovir disoproxil fumarate + emtricitabine + ethinyl estradiol + levonorgestrel.